Efficacy of adjuvant therapy with somatostatin analogues in recurrent type I gastric neuroendocrine tumors
Authors:
- K. R. GadzhievaKGK. R. Gadzhieva
- Yа. A. ZhulikovYZYа. A. Zhulikov
- A. A. MarkovichAMA. A. Markovich
- E. V. EvdokimovaEEE. V. Evdokimova
- V. A. GorbunovaVGV. A. Gorbunova
- G. S. EmelyanovaGEG. S. Emelyanova
- O. A. MalikhovaOMO. A. Malikhova
- I. A. KarasevIKI. A. Karasev
- A. A. KuznetsovaAKA. A. Kuznetsova
- V. V. DelektorskayaVDV. V. Delektorskaya
- A. K. KachmazovaAKA. K. Kachmazova
- E. V. ArtamonovaEAE. V. Artamonova
- 26 July 2025
- journal article
- Published by Alfmed LLC in Medical alphabet
- No. 14,p. 11-15
Abstract
Introduction. Neuroendocrine gastric tumor (gNETs) type 1 associated with chronic autoimmune atrophic gastritis, hypergastrinemia and usually have multifocal lesions and high frequency of local recurrence (~70 % for 2 year). Somatostatin analogs (SA) showed promised data in neoadjuvant setting with 84 % of complete response in meta-analysis. The aim of this study was to evaluate efficacy adjuvant treatment with SA for recurrent gNETs type 1. Methods. This retrospective, single center study included patients (pts) with recurrent gNETs who received adjuvant treatment with SA. Recruitment of pts was carried from 2012 to February 2024. Results. The study included 35 pts, 33 females and 2 males. Endoscopic mucosal resection (EMR) was performed in 34 cases (97.1 %), gastric resection in 1 (2.9 %). The median of previous EMR was 2 (1–6). The most of pts have multifocal lesions – 28 (80 %), the median of lesions is 5. Tumor size >10 mm was observed at 2 cases (5.7 %), the median size – 6 mm. One pts had N+. The median of Ki67 was 3,5 % (1–10 %), 21 (60 %) pts have G2 tumors and 14 (40 %) – G1. All pts received adjuvant therapy with SA, 33 (94.3 %) long-active octreotide 30 mg and 2 (5.7 %) lanreotide 120 mg. The time of SA therapy was Conclusions. Adjuvant therapy with somatostatin analogs significantly reduced gastrin levels and improved disease-free survival, demonstrating their antiproliferative effect in type 1 gastric neuroendocrine tumors. However, given the favorable prognosis and low risk of regional or distant metastases, the role of these agents in the treatment of gastric NETs requires further clarification in prospective studies.Keywords
This publication has 21 references indexed in Scilit:
- Neuroendocrine tumors in the stomach: An epidemiological analysis of Belgian Cancer Registry data 2010–2019Journal of Neuroendocrinology, 2024
- European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1–G3Journal of Neuroendocrinology, 2023
- Incidence and survival of neuroendocrine neoplasms in China with comparison to the United StatesChinese Medical Journal, 2023
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United StatesJAMA Oncology, 2017
- Zollinger–Ellison Syndrome: Still a Diagnostic Challenge in the 21st Century?Gastroenterology, 2011
- Treatment of type I gastric neuroendocrine tumors with somatostatin analogsJournal of Gastroenterology and Hepatology, 2010
- Review article: pathogenesis and management of gastric carcinoid tumoursAlimentary Pharmacology & Therapeutics, 2006
- Gastric CarcinoidsAnnals of Surgery, 2005
- Gastric Carcinoids and Neuroendocrine Carcinomas: Pathogenesis, Pathology, and BehaviorWorld Journal of Surgery, 1996
- Clinical Management of Gastric Carcinoid TumorsDigestion, 1994